Janssen Inc.
Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
---|---|---|
British Columbia's Expensive Drugs for Rare Diseases (EDRD) program. Specifically the proposed delivery of a universal pharmacare program.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
British Columbia's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health
|
Development of a joint industry-Government of British Columbia Life Sciences Sector Strategy
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health
|
Ministry of Health's Pharmaceutical Care Services Management Strategy
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
National Pharmacare. Specifically the proposed delivery of a universal pharmacare program.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Reimbursement of patented medicines
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Special Authority Transformation (SAT project)
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Subsequent Entry Biologics & policies related to their reimbursement.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Support British Columbia’s policy and regulatory framework to create a favourable business environment for the development of the life science sector.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Science and Technology
|